$PCRX
Pacira Biosciences Inc Stock $pcrx

$pcrx Overview Financials Valuation SEC Filings Company Website

2012 Q2 Form 10-Q Financial Statement

#000110465912056332 Filed on August 09, 2012

Income Statement

Concept	2012 Q2	2011 Q2
Revenue	$12.34M	$3.636M
YoY Change	239.49%	17.29%
Cost Of Revenue	$6.685M	$3.115M
YoY Change	114.61%	11.25%
Gross Profit	$5.659M	$521.0K
YoY Change	986.18%	160.5%
Gross Profit Margin	45.84%	14.33%
Selling, General & Admin	$10.41M	$4.466M
YoY Change	133.16%	272.17%
% of Gross Profit	184.01%	857.2%
Research & Development	$1.872M	$4.586M
YoY Change	-59.18%	-0.3%
% of Gross Profit	33.08%	880.23%
Depreciation & Amortization	$0.00	$400.0K
YoY Change	-100.0%	-60.78%
% of Gross Profit	0.0%	76.78%
Operating Expenses	$18.97M	$12.17M
YoY Change	55.91%	106.22%
Operating Profit	-$6.626M	-$8.531M
YoY Change	-22.33%	49.67%
Interest Expense	$494.0K	$676.0K
YoY Change	-26.92%	-184.5%
% of Operating Profit
Other Income/Expense, Net	-$1.670M	-$232.0K
YoY Change	619.83%	-22.67%
Pretax Income	-$8.296M	-$8.800M
YoY Change	-5.73%	29.41%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.296M	-$8.763M
YoY Change	-5.33%	28.87%
Net Earnings / Revenue	-67.21%	-241.01%
Basic Earnings Per Share	-$0.27	-$0.51
Diluted Earnings Per Share	-$0.27	-$0.51
COMMON SHARES
Basic Shares Outstanding	30.95M shares	17.23M shares
Diluted Shares Outstanding	30.95M shares	17.23M shares

Balance Sheet

Concept	2012 Q2	2011 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$84.30M	$47.20M
YoY Change	78.6%
Cash & Equivalents	$21.45M	$27.45M
Short-Term Investments	$62.80M	$19.80M
Other Short-Term Assets	$3.200M	$3.500M
YoY Change	-8.57%
Inventory	$9.299M	$1.900M
Prepaid Expenses
Receivables	$3.200M	$1.100M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$100.1M	$53.60M
YoY Change	86.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$29.97M	$24.60M
YoY Change	21.81%
Goodwill	$8.000M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$600.0K	$1.100M
YoY Change	-45.45%
Total Long-Term Assets	$42.78M	$33.50M
YoY Change	27.69%
TOTAL ASSETS
Total Short-Term Assets	$100.1M	$53.60M
Total Long-Term Assets	$42.78M	$33.50M
Total Assets	$142.9M	$87.10M
YoY Change	64.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$400.0K	$5.100M
YoY Change	-92.16%
Accrued Expenses	$9.300M	$3.600M
YoY Change	158.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.200M	$6.300M
YoY Change	-80.95%
Total Short-Term Liabilities	$15.24M	$17.50M
YoY Change	-12.94%
LONG-TERM LIABILITIES
Long-Term Debt	$25.90M	$22.60M
YoY Change	14.6%
Other Long-Term Liabilities	$7.200M	$24.10M
YoY Change	-70.12%
Total Long-Term Liabilities	$33.10M	$46.70M
YoY Change	-29.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.24M	$17.50M
Total Long-Term Liabilities	$33.10M	$46.70M
Total Liabilities	$48.35M	$64.20M
YoY Change	-24.69%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)		$2.000K
YoY Change
Treasury Stock Shares	1.065K shares
Shareholders Equity	$94.51M	$22.90M
YoY Change
Total Liabilities & Shareholders Equity	$142.9M	$87.10M
YoY Change	64.06%

Cashflow Statement

Concept	2012 Q2	2011 Q2
OPERATING ACTIVITIES
Net Income	-$8.296M	-$8.763M
YoY Change	-5.33%	28.87%
Depreciation, Depletion And Amortization	$0.00	$400.0K
YoY Change	-100.0%	-60.78%
Cash From Operating Activities	-$20.22M	-$10.92M
YoY Change	85.16%	28.02%
INVESTING ACTIVITIES
Capital Expenditures	-$4.370M	-$1.210M
YoY Change	261.16%	-19.33%
Acquisitions
YoY Change
Other Investing Activities	-$43.18M	-$19.76M
YoY Change	118.52%
Cash From Investing Activities	-$47.54M	-$20.96M
YoY Change	126.81%	1297.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$62.90M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	64.00M	0.000
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-20.22M	-10.92M
Cash From Investing Activities	-47.54M	-20.96M
Cash From Financing Activities	64.00M	0.000
Net Change In Cash	-3.760M	-31.88M
YoY Change	-88.21%	-1871.11%
FREE CASH FLOW
Cash From Operating Activities	-$20.22M	-$10.92M
Capital Expenditures	-$4.370M	-$1.210M
Free Cash Flow	-$15.85M	-$9.710M
YoY Change	63.23%	38.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6900000	shares
CY2012Q2	us-gaap	Share Price SharePrice	9.75
	pcrx	Number Of Major Customers NumberOfMajorCustomers	3	item
CY2011	pcrx	Number Of Major Customers NumberOfMajorCustomers	2	item
CY2011Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	25000	USD
CY2011Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	29970000	USD
CY2011Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	10000	USD
CY2011Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	18537000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46168000	USD
CY2011Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1299000	USD
CY2011Q4	us-gaap	Short Term Investments ShortTermInvestments	29985000	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2113000	USD
CY2011Q4	us-gaap	Inventory Net InventoryNet	1245000	USD
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1839000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	82649000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25103000	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	479000	USD
CY2011Q4	us-gaap	Assets Assets	113490000	USD
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3440000	USD
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7159000	USD
CY2011Q4	pcrx	Royalty Interest Obligation Current RoyaltyInterestObligationCurrent	1219000	USD
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13054000	USD
CY2011Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	7039000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31911000	USD
CY2011Q4	pcrx	Royalty Interest Obligation Noncurrent RoyaltyInterestObligationNoncurrent	1537000	USD
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	8416000	USD
CY2011Q4	pcrx	Contingent Purchase Liability ContingentPurchaseLiability	2042000	USD
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2778000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	65221000	USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q2	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	25000	USD
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	228470000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-180239000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	15000	USD
CY2011Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	48269000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	113490000	USD
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	94505000	USD
CY2012Q2	us-gaap	Liabilities Liabilities	48348000	USD
CY2012Q2	us-gaap	Liabilities Current LiabilitiesCurrent	15236000	USD
CY2012Q2	us-gaap	Assets Assets	142853000	USD
CY2012Q2	us-gaap	Assets Current AssetsCurrent	100076000	USD
CY2012Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2012Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32420472	shares
CY2012Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32419407	shares
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25340103	shares
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25339038	shares
CY2012Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	1065	shares
CY2011Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1065	shares
CY2011Q2	pcrx	Supply And Royalty Revenue SupplyAndRoyaltyRevenue	1469000	USD
CY2011Q2	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	1283000	USD
CY2011Q2	us-gaap	Revenues Revenues	3636000	USD
	pcrx	Supply And Royalty Revenue SupplyAndRoyaltyRevenue	3185000	USD
	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	2493000	USD
	us-gaap	Revenues Revenues	7500000	USD
CY2011Q2	us-gaap	Cost Of Revenue CostOfRevenue	3115000	USD
CY2011Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4586000	USD
CY2011Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4466000	USD
CY2011Q2	us-gaap	Operating Expenses OperatingExpenses	12167000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	6781000	USD
CY2011Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8531000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8382000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7988000	USD
	us-gaap	Operating Expenses OperatingExpenses	23151000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15651000	USD
CY2011Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	37000	USD
CY2011Q2	us-gaap	Interest Expense InterestExpense	676000	USD
CY2011Q2	us-gaap	Royalty Expense RoyaltyExpense	-429000	USD
CY2011Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-22000	USD
CY2011Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-232000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	65000	USD
	us-gaap	Interest Expense InterestExpense	3157000	USD
	us-gaap	Royalty Expense RoyaltyExpense	-118000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	88000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2886000	USD
CY2011Q2	us-gaap	Net Income Loss NetIncomeLoss	-8763000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18537000	USD
CY2011Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.36
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-8296000	USD
CY2012Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	81000	USD
CY2012Q2	us-gaap	Revenues Revenues	12344000	USD
	us-gaap	Revenues Revenues	20148000	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	18970000	USD
	us-gaap	Operating Expenses OperatingExpenses	37911000	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6626000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17763000	USD
CY2012Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1670000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2427000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20190000	USD
CY2011Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8763000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18537000	USD
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8215000	USD
CY2012Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	81000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	83000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20107000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	83000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-14910000	USD
	us-gaap	Interest Paid InterestPaid	2360000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	907000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	51222000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	6000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	1317000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26133000	USD
CY2011Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27450000	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21445000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-37774000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-24723000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	383000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1751000	USD
	dei	Entity Registrant Name EntityRegistrantName	Pacira Pharmaceuticals, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001396814
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2012-06-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2012Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32419407	shares
CY2012Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3339000	USD
CY2012Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1432000	USD
CY2012Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4528000	USD
CY2012Q2	us-gaap	Inventory Net InventoryNet	9299000	USD
CY2011Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	862000	USD
CY2011Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	96000	USD
CY2011Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	287000	USD
CY2012Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	0	USD
CY2012Q2	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	500000	USD
	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	900000	USD
CY2012Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	40107000	USD
CY2012Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10141000	USD
CY2012Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	29966000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	33385000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1751000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1100000	USD
CY2012Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	USD
CY2012Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	322000	USD
CY2012Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	753000	USD
CY2012Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2050000	USD
CY2012Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1026000	USD
CY2012Q2	pcrx	Royalty Interest Obligation Current RoyaltyInterestObligationCurrent	1164000	USD
CY2012Q2	pcrx	Royalty Interest Obligation Noncurrent RoyaltyInterestObligationNoncurrent	1270000	USD
CY2012Q2	pcrx	Long Term Debt Including Royalty Interest Obligation LongTermDebtIncludingRoyaltyInterestObligation	27104000	USD
CY2011Q4	pcrx	Long Term Debt Including Royalty Interest Obligation LongTermDebtIncludingRoyaltyInterestObligation	28332000	USD
CY2011Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	551000	USD
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	996836	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	4207701	shares
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	5204537	shares
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1040000	USD
CY2012Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30954000	shares
CY2012Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30954000	shares
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2011Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17233000	shares
CY2011Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17233000	shares
CY2011Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2011Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28160000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28160000	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13624000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13624000	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.36
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.36
	pcrx	Potential Weighted Average Number Of Diluted Shares Outstanding PotentialWeightedAverageNumberOfDilutedSharesOutstanding	14979000	shares
CY2011Q2	pcrx	Potential Weighted Average Number Of Diluted Shares Outstanding PotentialWeightedAverageNumberOfDilutedSharesOutstanding	18560000	shares
	pcrx	Potential Weighted Average Number Of Diluted Shares Outstanding PotentialWeightedAverageNumberOfDilutedSharesOutstanding	29467000	shares
CY2012Q2	pcrx	Potential Weighted Average Number Of Diluted Shares Outstanding PotentialWeightedAverageNumberOfDilutedSharesOutstanding	32288000	shares
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8282000	USD
CY2011Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1523000	USD
CY2011Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	400000	USD

Files In Submission

Name	View Source	Status
0001104659-12-056332-index-headers.html	Edgar Link	pending
0001104659-12-056332-index.html	Edgar Link	pending
0001104659-12-056332.txt	Edgar Link	pending
0001104659-12-056332-xbrl.zip	Edgar Link	pending
a12-13989_110q.htm	Edgar Link	pending
a12-13989_1ex10d1.htm	Edgar Link	pending
a12-13989_1ex10d2.htm	Edgar Link	pending
a12-13989_1ex10d3.htm	Edgar Link	pending
a12-13989_1ex10d4.htm	Edgar Link	pending
a12-13989_1ex10d5.htm	Edgar Link	pending
a12-13989_1ex10d6.htm	Edgar Link	pending
a12-13989_1ex31d1.htm	Edgar Link	pending
a12-13989_1ex31d2.htm	Edgar Link	pending
a12-13989_1ex32d1.htm	Edgar Link	pending
a12-13989_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g139891kc17i001.jpg	Edgar Link	pending
pcrx-20120630.xml	Edgar Link	completed
pcrx-20120630.xsd	Edgar Link	pending
pcrx-20120630_cal.xml	Edgar Link	unprocessable
pcrx-20120630_def.xml	Edgar Link	unprocessable
pcrx-20120630_lab.xml	Edgar Link	unprocessable
pcrx-20120630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCRX
Pacira Biosciences Inc Stock $pcrx

2012 Q2 Form 10-Q Financial Statement

#000110465912056332 Filed on August 09, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX Pacira Biosciences Inc Stock $pcrx

2012 Q2 Form 10-Q Financial Statement

#000110465912056332 Filed on August 09, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX
Pacira Biosciences Inc Stock $pcrx